Background Chemo-radiotherapy is standard of care in the treatment of unresectable stage III NSCLC. We aimed at assessing whether the addition of concurrent taxane-chemotherapy to thoracic irradiation following chemotherapy was able to improve treatment outcome. Material and methods In PITCAP trial, patients with unresectable stage III NSCLC were randomized to receive 2 cycles of platinum-paclitaxel followed by 60–61.2 Gy thoracic irradiation (control arm) or by same radiotherapy with concomitant weekly paclitaxel (experimental arm). A literature-based meta-analysis including all studies with same design was also performed. Results At the time of the second interim analysis, when 151 patients were randomized, accrual was terminated. With a median follow-up of 6.1 years, median survival was 13.2 vs 15.1 months, with a 3-year survival rate of 19.5 vs 21.2% in the control and experimental arm, respectively (HR: 0.97; 95% CI 0.69–1.36; p = 0.845). Treatment toxicity was manageable in both arms. The meta-analysis of 5 trials (n = 866) confirmed the lack of a meaningful effect on 1-year overall survival of a taxane added concurrently to radiotherapy. Conclusions These results do not support a meaningful survival benefit with the addition of single agent taxane given concurrently to radiotherapy after platinum-based induction in locally advanced NSCLC.

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC / Ardizzoni, Andrea; Tiseo, Marcello; Boni, Luca; Di Maio, Massimo; Buffoni, Lucio; Belvedere, Ornella; Grossi, Francesco; D'Alessandro, Vito; de Marinis, Filippo; Barbera, Santi; Caroti, Cinzia; Favaretto, Adolfo; Cortinovis, Diego; Morrica, Brunello; Tixi, Lucia; Ceschia, Tino; Parisi, Salvatore; Ricardi, Umberto; Grimaldi, Andrea; Loreggian, Lucio; Navarria, Pierina; Huber, Rudolf M.; Belani, Chandra; Bruswig, Paal Fr; Scagliotti, Giorgio Vittorio; Scolaro, Tindaro. - In: LUNG CANCER. - ISSN 0169-5002. - 100:(2016), pp. 30-37. [10.1016/j.lungcan.2016.07.026]

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC

Tiseo, Marcello
;
2016-01-01

Abstract

Background Chemo-radiotherapy is standard of care in the treatment of unresectable stage III NSCLC. We aimed at assessing whether the addition of concurrent taxane-chemotherapy to thoracic irradiation following chemotherapy was able to improve treatment outcome. Material and methods In PITCAP trial, patients with unresectable stage III NSCLC were randomized to receive 2 cycles of platinum-paclitaxel followed by 60–61.2 Gy thoracic irradiation (control arm) or by same radiotherapy with concomitant weekly paclitaxel (experimental arm). A literature-based meta-analysis including all studies with same design was also performed. Results At the time of the second interim analysis, when 151 patients were randomized, accrual was terminated. With a median follow-up of 6.1 years, median survival was 13.2 vs 15.1 months, with a 3-year survival rate of 19.5 vs 21.2% in the control and experimental arm, respectively (HR: 0.97; 95% CI 0.69–1.36; p = 0.845). Treatment toxicity was manageable in both arms. The meta-analysis of 5 trials (n = 866) confirmed the lack of a meaningful effect on 1-year overall survival of a taxane added concurrently to radiotherapy. Conclusions These results do not support a meaningful survival benefit with the addition of single agent taxane given concurrently to radiotherapy after platinum-based induction in locally advanced NSCLC.
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC / Ardizzoni, Andrea; Tiseo, Marcello; Boni, Luca; Di Maio, Massimo; Buffoni, Lucio; Belvedere, Ornella; Grossi, Francesco; D'Alessandro, Vito; de Marinis, Filippo; Barbera, Santi; Caroti, Cinzia; Favaretto, Adolfo; Cortinovis, Diego; Morrica, Brunello; Tixi, Lucia; Ceschia, Tino; Parisi, Salvatore; Ricardi, Umberto; Grimaldi, Andrea; Loreggian, Lucio; Navarria, Pierina; Huber, Rudolf M.; Belani, Chandra; Bruswig, Paal Fr; Scagliotti, Giorgio Vittorio; Scolaro, Tindaro. - In: LUNG CANCER. - ISSN 0169-5002. - 100:(2016), pp. 30-37. [10.1016/j.lungcan.2016.07.026]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2852830
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact